Literature DB >> 8132222

Synergistic effect of IL-4 and TNF-alpha in the induction of monocytic differentiation of a mouse myeloid leukaemic cell line (WEHI-3B JCS).

K N Leung1, N K Mak, M C Fung, A J Hapel.   

Abstract

We have previously shown that non-cytotoxic concentrations (600-1200 U/ml) of recombinant mouse tumour necrosis factor-alpha (TNF-alpha) can induce differentiation of a subclone (JCS) of the WEHI-3B myelomonocytic leukaemia cell line into mature cells with the characteristics of macrophages. In the present study, the effects of recombinant mouse interleukin-4 (IL-4), either alone or in combination with mouse TNF-alpha, on the growth and differentiation of JCS cells were examined. IL-4 alone (20-5000 U/ml) inhibited the growth of JCS cells in a dose-dependent manner but did not induce cell differentiation. However, combinations of IL-4 and TNF-alpha acted in synergy to inhibit cell proliferation and induce monocytic differentiation of JCS cells, as shown by increased expression of the macrophage differentiation antigens (F4/80, Mac-1), stimulation of phagocytic activity, induction of non-specific esterase and NBT-reducing activities, increased plastic adherence and morphological criteria. Similar synergistic interactions were also shown by human TNF-alpha and mouse IL-4, indicating that TNF-alpha might exert its effects through the low-affinity (p55) TNF receptors. Moreover, the clonogenicity of JCS cells in vitro and their tumorigenicity in vivo were significantly reduced by combined TNF-alpha and IL-4 treatment. Our results indicate that TNF-alpha can act as a differential signal for JCS cells and that its effects are modulated by IL-4. Therefore, the combination of TNF-alpha and IL-4 may be useful in the treatment of some forms of myelomonocytic leukaemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132222      PMCID: PMC1422298     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

1.  Monocytic differentiation of a myelomonocytic leukemic cell (WEHI 3B JCS) is induced by tumour necrosis factor-alpha (TNF-alpha).

Authors:  N K Mak; M C Fung; K N Leung; A J Hapel
Journal:  Cell Immunol       Date:  1993-08       Impact factor: 4.868

2.  Role of biologic response modifiers in the growth and differentiation of myeloid leukemic cells.

Authors:  F Ruscetti; G Sing; P Burke; F Bettens; E Schlick; S Ruscetti; J Keller
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

3.  Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro. Relationship to cell surface receptor.

Authors:  C Peetre; U Gullberg; E Nilsson; I Olsson
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

4.  Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes.

Authors:  M Wieser; R Bonifer; W Oster; A Lindemann; R Mertelsmann; F Herrmann
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

5.  Actions and interactions of G-CSF, LIF, and IL-6 on normal and leukemic murine cells.

Authors:  D Metcalf
Journal:  Leukemia       Date:  1989-05       Impact factor: 11.528

6.  Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4.

Authors:  A A te Velde; J P Klomp; B A Yard; J E de Vries; C G Figdor
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

7.  Synergistic interactions of interleukin 1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor.

Authors:  K Onozaki; H Urawa; T Tamatani; Y Iwamura; T Hashimoto; T Baba; H Suzuki; M Yamada; S Yamamoto; J J Oppenheim
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

Review 8.  B-cell stimulatory factor-1/interleukin 4.

Authors:  W E Paul; J Ohara
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

9.  Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hemopoietic progenitor cells.

Authors:  D Rennick; G Yang; C Muller-Sieburg; C Smith; N Arai; Y Takabe; L Gemmell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

10.  Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon.

Authors:  G Trinchieri; M Kobayashi; M Rosen; R Loudon; M Murphy; B Perussia
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

2.  IL-4 and IL-13 stimulate human bronchial epithelial cells to release IL-8.

Authors:  I Stríz; T Mio; Y Adachi; R A Robbins; D J Romberger; S I Rennard
Journal:  Inflammation       Date:  1999-12       Impact factor: 4.092

3.  Tumor necrosis factor-alpha enhances DMSO-induced differentiation of HL-60 cells through the activation of ERK/MAPK pathway.

Authors:  Hong-Nu Yu; Young-Rae Lee; Eun-Mi Noh; Kyung-Sun Lee; Eun-Kyung Song; Myung-Kwan Han; Yong-Chul Lee; Chang-Yeol Yim; Jinny Park; Byeong-Soo Kim; Sung-Ho Lee; Seung Jin Lee; Jong-Suk Kim
Journal:  Int J Hematol       Date:  2008-02-08       Impact factor: 2.490

4.  Influence of Biomimetically Mineralized Collagen Scaffolds on Bone Cell Proliferation and Immune Activation.

Authors:  Lucie Bacakova; Katarina Novotna; Daniel Hadraba; Jana Musilkova; Petr Slepicka; Milos Beran
Journal:  Polymers (Basel)       Date:  2022-02-03       Impact factor: 4.329

5.  Inhibitors of Human Neuraminidase Enzymes Block Transmigration in vitro.

Authors:  Md Amran Howlader; Tianlin Guo; Christopher W Cairo
Journal:  Front Mol Biosci       Date:  2022-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.